Psychological outcomes of evening and night closed‐loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2‐month randomized crossover trial
Open Access
- 1 October 2016
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 34 (2), 262-271
- https://doi.org/10.1111/dme.13268
Abstract
Aim To assess the impact on fear of hypoglycaemia and treatment satisfaction with an artificial pancreas system used for 2 consecutive months, as well as participant acceptance of the artificial pancreas system. Methods In a randomized crossover trial patient‐related outcomes associated with an evening‐and‐night artificial pancreas and sensor‐augmented pump therapy were compared. Both intervention periods lasted 8 weeks. The artificial pancreas acceptance questionnaire (range 0–90, higher scores better), Hypoglycaemia Fear Survey II (range 0–72, higher scores worse) and Diabetes Treatment Satisfaction Questionnaire (range 0–36, higher scores better) were completed by 32 participants. Semi‐structured interviews were conducted after study completion in a subset of six participants. Outcomes were compared using a repeated‐measures anova model or paired t‐test when appropriate. Results The total artificial pancreas acceptance questionnaire score at the end of the artificial pancreas period was 69.1 (sd 14.7; 95% CI 63.5, 74.7), indicating a positive attitude towards the artificial pancreas. No significant differences were found among the scores at baseline, end of sensor‐augmented pump therapy period or end of the artificial pancreas period with regard to fear of hypoglycaemia [28.2 (sd 17.5), 23.5 (sd 16.6) and 23.5 (sd 16.7), respectively; P = 0.099] or diabetes treatment satisfaction [29.0 (sd 3.9), 28.2 (sd 5.2) and 28.0 (sd 7.1), respectively; P = 0.43]. Themes frequently mentioned in the interviews were ‘positive effects at work’, ‘improved blood glucose’, ‘fewer worries about blood glucose’, but also ‘frequent alarms’, ‘technological issues’ and ‘demand for an all‐in‐one device’. Conclusions The psychological outcomes of artificial pancreas and sensor‐augmented pump therapy were similar. Current artificial pancreas technology is promising but user concerns should be taken into account to ensure utility of these systems.Keywords
Funding Information
- Seventh Framework Programme (247138)
This publication has 12 references indexed in Scilit:
- Home Use of an Artificial Beta Cell in Type 1 DiabetesNew England Journal of Medicine, 2015
- Psychosocial aspects of closed‐ and open‐loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home settingDiabetic Medicine, 2015
- MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover TrialDiabetes Care, 2014
- Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Diabetes Care 2014;37:1191–1197Diabetes Care, 2014
- Artificial Pancreas (AP) Clinical Trial Participants' Acceptance of Future AP TechnologyDiabetes Technology & Therapeutics, 2014
- Examining the Behaviour subscale of the Hypoglycaemia Fear Survey: an international studyDiabetic Medicine, 2013
- Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient dataBMJ, 2011
- Future Acceptance of an Artificial Pancreas in Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2011
- Beliefs about insulin as a predictor of fear of hypoglycaemiaChronic Illness, 2009
- Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated DiabetesDiabetic Medicine, 1990